Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial

Study (n=68) reports that in the 42 evaluable patients, there was one complete response and seven partial responses (objective response rate 19%, 95% CI 9–34) at median follow-up of 61.2 months.

SPS commentary:

A related commentary suggests, cabozantinib, a multikinase inhibitor, has single-agent clinical activity in patients with heavily pretreated, platinum-refractory metastatic urothelial carcinoma with measurable disease and bone metastases and is generally well tolerated. It adds that as cabozantinib has innate and adaptive immunomodulatory properties, there is a rationale for combining it with immunotherapeutic strategies.


The Lancet Oncology

Resource links: